- Home
- ECOR vs LITS Comparison
ECOR vs LITS Comparison
Compare ECOR & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECOR | LITS |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.0M | 41.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ECOR | LITS |
|---|---|---|
| Price | $6.25 | $1.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 67.0K | ★ 243.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,032,000.00 | N/A |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.20 | N/A |
| 52 Week Low | $4.16 | $0.95 |
| 52 Week High | $8.55 | $3.03 |
Technical Indicators
Market Signals| Indicator | ECOR | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 49.54 |
| Support Level | $4.65 | $0.98 |
| Resistance Level | $6.94 | $1.16 |
| Average True Range (ATR) | 0.65 | 0.06 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 46.45 | 52.38 |
Price Performance
Historical ComparisonAbout ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.